



# Market Announcement

28 July 2023

---

## Starpharma Holdings Limited (ASX: SPL) – Trading Halt

### Description

The securities of Starpharma Holdings Limited ('SPL') will be placed in trading halt at the request of SPL, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 1 August 2023 or when the announcement is released to the market.

### Issued by

**Melissa Kostopoulos**

Adviser, Listings Compliance



**Starpharma Holdings Limited**  
A.B.N. 20 078 532 180

4-6 Southampton Crescent  
Abbotsford Victoria 3067 Australia

PO Box 2022  
Preston Victoria 3072 Australia

Telephone (+613) 8532 2700  
Facsimile (+613) 9510 5955  
[www.starpharma.com](http://www.starpharma.com)

Attention: Melissa Kostopoulos

ASX Compliance Pty Ltd  
South Tower Level 50, Rialto  
525 Collins Street  
Melbourne VIC 3000

28 July 2023

Dear Melissa,

**Starpharma Holdings Limited (ASX:SPL) – Request for a trading halt**

In accordance with Listing Rule 17.1, Starpharma Holdings Limited (**Starpharma**) requests a trading halt in its securities pending an announcement to the market regarding a partnered program. Starpharma expects that the announcement will be made prior to the opening of trading on Tuesday, 1st August 2023.

Accordingly, the trading halt should remain in place until the earlier of the opening of trading on Tuesday 1<sup>st</sup> August 2023 or when Starpharma makes an announcement in relation to the partnered program.

Starpharma is not aware of any reason why the trading halt should not be granted by ASX.

Yours sincerely,

A handwritten signature in blue ink, appearing to read "Justin Cahill", with a large, stylized flourish at the end.

Justin Cahill  
Chief Financial Officer & Company Secretary  
Starpharma Holdings Limited